Halozyme Therapeutics, Inc. (HALO)
- Previous Close
38.46 - Open
38.46 - Bid 38.53 x 200
- Ask 38.58 x 200
- Day's Range
38.46 - 39.02 - 52 Week Range
29.85 - 45.00 - Volume
525,090 - Avg. Volume
1,016,933 - Market Cap (intraday)
4.9B - Beta (5Y Monthly) 1.25
- PE Ratio (TTM)
18.37 - EPS (TTM)
2.10 - Earnings Date May 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
51.11
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
halozyme.comRecent News: HALO
Performance Overview: HALO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HALO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HALO
Valuation Measures
Market Cap
4.90B
Enterprise Value
6.06B
Trailing P/E
18.37
Forward P/E
12.61
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.24
Price/Book (mrq)
58.47
Enterprise Value/Revenue
7.31
Enterprise Value/EBITDA
13.42
Financial Highlights
Profitability and Income Statement
Profit Margin
33.96%
Return on Assets (ttm)
11.89%
Return on Equity (ttm)
222.07%
Revenue (ttm)
829.25M
Net Income Avi to Common (ttm)
281.59M
Diluted EPS (ttm)
2.10
Balance Sheet and Cash Flow
Total Cash (mrq)
336M
Total Debt/Equity (mrq)
1,827.33%
Levered Free Cash Flow (ttm)
268.16M
Research Analysis: HALO
Company Insights: HALO
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: HALO
HALO: Raising target price to $41.00
HALOZYME THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $41.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetHALO: Lowering target price to $40.00
HALOZYME THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $40.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetHALO: What does Argus have to say about HALO?
HALOZYME THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $42.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetHALO: What does Argus have to say about HALO?
HALOZYME THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $42.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target